Interestingly, it would appear that TEN-010 could never have been considered for Grand Challenge 6 funded by CRUK. The Grand Challenge Advisory Panel will only consider applications which ' focus upon targeting the Myc protein itself'. As far as I understand, the drug acquired by Roche doesn't directly target Myc but rather targets one of the collaborators of Myc - a bromodomain inhibitor.
Applications for the Grand Challenge close 12 February 2016. I must say that the Dana-Farber Cancer Institute would make an outstanding co-investigator for the Myc challenge in light of their pioneering work on Myc over the last decade.
Interestingly, it would appear that TEN-010 could never have...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.28 |
Change
0.020(1.59%) |
Mkt cap ! $743.6M | |||
| Open | High | Low | Value | Volume |
| $1.26 | $1.28 | $1.24 | $46.67K | 37.07K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15857 | $1.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.30 | 700 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |